PBH as reported
Prestige Consumer Healthcare Inc. reported $1.09B of revenue over the trailing twelve months, −4.3% on the year before. 11 reported series are charted on this page, each one as filed.
$1.09B
Revenue, trailing twelve months · to Q4 2026 · −4.3% against the twelve months before
- Net Income
- $190M
Net Income · −11% year on year · trailing twelve months to Q4 2026
- Free Cash Flow
- $246M
Free Cash Flow · +1.3% year on year · trailing twelve months to Q4 2026
- Op Margin
- 28%
Op Margin · trailing twelve months to Q4 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $1.09B | −4.3% | Q4 2026 |
| Net Income | $190M | −11% | Q4 2026 |
| EPS | $3.91 | −9.1% | Q4 2026 |
| Gross Margin | 55% | n/a | Q4 2026 |
| Op Margin | 28% | n/a | Q4 2026 |
| Net Margin | 18% | n/a | Q4 2026 |
| ROE | 11% | n/a | Q4 2026 |
| ROA | 5.7% | n/a | Q4 2026 |
| ROIC | 9.3% | n/a | Q4 2026 |
| Free Cash Flow | $246M | +1.3% | Q4 2026 |
| P/E | 13.3 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Prestige Consumer Healthcare Inc. (PBH) - Revenue & ProfitRevenue & ProfitPrestige Consumer Healthcare Inc. (PBH)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
Ranks #9 of 28 by Smart Score